The biomarker landscape in mycosis fungoides and Sézary syndrome

Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E. Akilov

doi:10.1111/exd.13261

journal article Open Access Feb 02, 2017

The biomarker landscape in mycosis fungoides and Sézary syndrome

Brittany Dulmage Larisa Geskin Joan Guitart

Oleg E. Akilov

Experimental Dermatology Vol. 26 No. 8 pp. 668-676 · Wiley

View at Publisher Save 10.1111/exd.13261

Abstract

AbstractThe practice of pre‐emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T‐cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

Topics

No keywords indexed for this article. Browse by subject →

References

105

[1]

10.1182/blood-2004-09-3502

[2]

10.1016/s0190-9622(09)80056-x

[3]

10.1016/s0889-8588(18)30055-8

[4]

10.1001/archderm.1981.01650070036020

[5]

Olerud J. E. Arch. Dermatol. (1992) 10.1001/archderm.1992.01680140081007

[6]

10.1001/archderm.136.4.497

[7]

10.1016/s0190-9622(98)70505-5

[8]

10.1038/sj.jid.5701109

[9]

10.1001/archderm.139.7.857

[10]

10.1200/jco.2015.61.7142

[11]

10.3748/wjg.v21.i41.11636

[12]

Zattra E. Eur. J. Dermatol. (2012) 10.1684/ejd.2011.1569

[13]

10.1182/blood-2007-03-055749

[14]

10.1111/bjd.12909

[15]

10.1182/blood.v97.3.624

[16]

Shipp M. A. Blood (1994) 10.1182/blood.v83.5.1165.1165

[17]

10.1016/s0190-9622(99)70079-4

[18]

10.1080/1042819021000054652

[19]

10.1111/j.1365-4632.2009.03771.x

[20]

10.1159/000327553

[21]

10.1159/000080852

[22]

10.1111/exd.12455

[23]

10.1182/blood-2014-07-590398

[24]

10.1016/j.clim.2015.02.014

[25]

10.2340/00015555-1958

[26]

10.2340/00015555-1345

[27]

10.1067/mjd.2003.132

[28]

10.1007/s13277-012-0379-2

[29]

10.1093/annonc/mdm007

[30]

10.1097/01243894-200607000-00003

[31]

10.1371/journal.pone.0008376

[32]

10.1001/archderm.140.9.1057

[33]

10.1111/j.1365-2133.2005.06755.x

[34]

10.1200/jco.2001.19.23.4322

[35]

10.1046/j.1523-1747.1999.00718.x

[36]

Diamandidou E. Blood (1998) 10.1182/blood.v92.4.1150

[37]

10.1080/10428190600709655

[38]

10.1182/blood-2010-05-287664

[39]

10.1097/00000372-199802000-00001

[40]

Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases

Marchina F. Benner, Patty M. Jansen, Maarten H. Vermeer et al.

Blood 10.1182/blood-2011-08-376319

[41]

10.1016/s0022-1759(00)00229-5

[42]

Chen X. N. Am. J. Med. Sci. (2010)

[43]

10.1111/j.1600-0560.1996.tb01302.x

[44]

10.1111/j.1365-2133.2008.08739.x

[45]

10.1182/blood.v100.9.3369

[46]

10.1126/scitranslmed.aaa9122

[47]

10.1182/blood-2004-06-2220

[48]

10.1111/j.1600-0560.2006.00560.x

[49]

10.1111/ijd.12847

[50]

10.1309/ajcp1na3ychcdeig

Showing 50 of 105 references

Cited By

27

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma

Konstantinos Seretis, Konstantinos Sfaelos · 2024

Cancers

Metrics

27

Citations

105

References

Details

Published: Feb 02, 2017
Vol/Issue: 26(8)
Pages: 668-676
License: View

Authors

B

Brittany Dulmage

Department of Dermatology University of Pittsburgh Pittsburgh PA USA

L

Larisa Geskin

Department of Dermatology Columbia University New York NY USA

J

Joan Guitart

Department of Dermatology Northwestern University Chicago IL USA

O

Oleg E. Akilov

Department of Dermatology University of Pittsburgh Pittsburgh PA USA

Cite This Article

Brittany Dulmage, Larisa Geskin, Joan Guitart, et al. (2017). The biomarker landscape in mycosis fungoides and Sézary syndrome. Experimental Dermatology, 26(8), 668-676. https://doi.org/10.1111/exd.13261

The biomarker landscape in mycosis fungoides and Sézary syndrome

You May Also Like